(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -43.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.27%.
Cytomx Therapeutics's revenue in 2025 is $147,557,000.On average, 10 Wall Street analysts forecast CTMX's revenue for 2025 to be $7,664,263,219, with the lowest CTMX revenue forecast at $6,129,153,179, and the highest CTMX revenue forecast at $9,565,716,414. On average, 10 Wall Street analysts forecast CTMX's revenue for 2026 to be $3,565,315,440, with the lowest CTMX revenue forecast at $0, and the highest CTMX revenue forecast at $8,634,540,480.
In 2027, CTMX is forecast to generate $2,935,743,763 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $9,481,064,057.